Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study.

Lee S W, Scheu R, Enkhtsetseg N, Hill J, Sadok J, Mastick M, Satish S, Mateen FJ

Lancet Reg Health Am. 2026 Dec; 64:101640. PMID: 42834886. Abstract